As the US undertakes historic revisions to its vaccine guidelines, a particular individual has surfaced somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by casting doubt on coronavirus shots in the pandemic and has concentrated on potential fatalities following Covid vaccination in her brief tenure at the FDA.
Agency leaders planned to announce radical revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US at odds with many the world with insufficient data for public health gain. This reveal has been pushed back until the next year.
In place of the director of the vaccine center, Tracy Beth Høeg is listed to address the audience at the gathering. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth individual to head the center this year.
This interim role may indicate a closer partnership between the drug and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a renewed priority upon reevaluating long-standing vaccines at the FDA.
Dr. Høeg has repeatedly called for halting some childhood vaccine recommendations in the US to become more similar to the Danish model, a nation with comprehensive healthcare and a number of inhabitants about the size of the state of Wisconsin.
To date statements, she has persisted in emphasizing on vaccines – usually the domain of Prasad, director of the FDA’s CBER – rather than medication approval.
Dr. Høeg has no obvious background in medication creation, regulation or administrative roles, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and CBER since spring.
“She doesn’t seem to have the necessary background” for leading the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in managing a large organization. She lacks background in industry regulation.”
Past directors of the center would “grasp regulatory frameworks and the science of drug development”, commented Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who headed CBER have had.”
The drug center has an enormous range of responsibilities at the agency, Woodcock pointed out.
“Everybody just focuses on the new drug program, but the off-patent medication office clears numerous generic drugs. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these have to be supervised,” Dr. Woodcock said. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”
Additionally, a significant leadership aspect to the job, which manages over 5,000 staff members. “It’s a huge management job, if you execute it properly,” the former official added.
In response to questions about Dr. Høeg's credentials and whether this assignment indicates greater collaboration among regulatory chiefs on immunizations, a spokesperson responded that the “questions are based on inaccurate assumptions”.
“Her resume aligns with the responsibilities of her role,” the official stated, citing the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and shot safety tracking”.
As acting director, Høeg takes over the agency head's recently launched fast-track approval initiative, a disputed one-day drug-approval program that allegedly concerned her preceding directors. “How are these therapies being chosen for this expedited pathway? Who takes the choices?” Howard said. “There’s a lot of lack of transparency happening at the regulatory body right now.”
In general, he remarked, “the FDA looks to be trending towards less stringent oversight of pharmaceuticals, with the exception of shots.”
Concerning vaccines, Dr. Høeg has a clearer, if concerning, history, critics observe. She published a study using non-validated public submissions to assess the incidence of heart inflammation after COVID-19 vaccination. She advised the state of Florida top health official Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccines are more dangerous than they are.
Part of her “wish list” for the current federal leadership included altering guidelines for new vaccines and ending “non-essential” immunizations, she stated after the election on a online show. At the FDA, Høeg has according to sources proposed barring teenage boys from receiving COVID-19 vaccinations.
“She is an thorough dogmatist who starts off with her preconceived notions and tailors the evidence to accommodate the evidence in a extremely disingenuous, fraudulent way,” Dr. Howard stated.
Høeg joined fellow contrarians, {like|
A seasoned gaming enthusiast with over a decade of experience in reviewing online casinos and sharing winning strategies.
